TAKE THIS POLL |
|
|
- Introgen to Host Conference Call with Clinical Investigators to Discuss Phase III Data and ADVEXIN Registration Activities 8 Jul 2008 19:47 GMT
... Drug Administration (FDA) requesting marketing approval for ADVEXIN p53 therapy to treat recurrent, refractory head and neck cancer. Simultaneously, Gendux Molecular Limited, an Introgen subsidiary, submitted a Marketing Authorization Application (MAA) to ...
- --> Cleveland BioLabs Granted First Patent for Protectan CBLB502 8 Jul 2008 12:56 GMT
... human safety studies in 2008. A Phase I/II medical trial for Protectan CBLB502 in head and neck cancer patients for reduction of radiation and chemotherapy toxicities is also expected to start later in ...
- Cleveland BioLabs Granted First Patent for Protectan CBLB502 8 Jul 2008 12:53 GMT
... human safety studies in 2008. A Phase I/II medical trial for Protectan CBLB502 in head and neck cancer patients for reduction of radiation and chemotherapy toxicities is also expected to start later in ...
- Some Experts Say Snuff Is A Safer Alternative To Cigarettes 7 Jul 2008 22:31 GMT
... campus. A practicing doctor for 40 years, he's seen too many patients suffering from head and neck cancer to ever defend smokeless tobacco. "There's just no excuse for that type of approach, regardless ...
- The Lesser of the Two: Some Experts Tout Snuff, Which is Gaining Popularity, As a Safer Alternative to Cigarettes. 7 Jul 2008 17:13 GMT
... campus. A practicing doctor for 40 years, he's seen too many patients suffering from head and neck cancer to ever defend smokeless tobacco. "There's just no excuse for that type of approach, regardless ...
- Introgen Reduces Development Staff to Focus on Commercial Activities after Advexin Regulatory Filings in U.S. and Europe 7 Jul 2008 12:30 GMT
... Drug Administration (FDA) requesting marketing approval for ADVEXIN p53 therapy to treat recurrent, refractory head and neck cancer. Simultaneously, Gendux Molecular Limited, an Introgen subsidiary, submitted a Marketing Authorization Application (MAA) to ...
- New cancer group launch date 7 Jul 2008 12:12 GMT
... Head Cancer Campaign has been set up to raise awareness of the symptoms of head and neck cancer and to encourage earlier diagnosis. The group will be working to develop the education of ...
- Hana Biosciences Presents Alocrest and Menadione Data At the European Society for Medical Oncology C 7 Jul 2008 11:31 GMT
... Hana Biosciences Presents Alocrest and Menadione Data At the European Society for Medical Oncology Conference Hana Biosciences ...
- Phase 2 Study Of IMC-A12 for Advanced Soft Tissue Sarcoma Opens for Patient Enrollment 7 Jul 2008 11:30 GMT
... Phase 2 Study Of IMC-A12 for Advanced Soft Tissue Sarcoma Opens for ... with advanced prostate, pancreatic, colorectal, liver, and head and neck cancers, as well as a series of Phase ...
- Hana Biosciences Presents Alocrest and Menadione Data At the European Society for Medical Oncology Conference 7 Jul 2008 11:15 GMT
... , a biopharmaceutical company focused on strengthening the foundation of cancer care, presented data for two of ...
- Introgen cuts 29% of jobs as it moves to market cancer therapy 6 Jul 2008 18:30 GMT
... months from the submission date to decide. Advexin p53 is designed to treat recurrent head and neck cancer. By harnessing the body's natural tumor-suppression mechanisms, the treatment fights cancer without some of ...
- Death Records for July 6, 2008 6 Jul 2008 07:34 GMT
... died June 21, congestive heart failure Justice, John C.; 65, Evansville, died June 18, head and neck cancer Kail, Marcus O.; 55, Freelandville, Ind., died May 31, aorta dissection Mayberry, Michael J.; 54, ...
1 - 25 of 48 next >
News by PR Newswire
|
